Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gabriela Plesa

Showing results (1-10 of 53) with videos related to

Pageof 6
Sort By:
Immunotherapy|August 4, 2017
Overcoming barriers of car T-cell therapy in patients with mesothelin-expressing cancersMark H O'Hara, Caitlin Stashwick, Gabriela Plesa, et al.
Journal of Immunology (Baltimore, Md. : 1950)|April 9, 2008
Derivation and fluidity of acutely induced dysfunctional CD8+ T cellsGabriela Plesa, Adam E Snook, Scott A Waldman, et al.
Journal of Virology|June 16, 2006
Immunogenicity of cytopathic and noncytopathic viral vectorsGabriela Plesa, Philip M McKenna, Matthias J Schnell, et al.
Journal of Virology|October 12, 2007
Addition of deoxynucleosides enhances human immunodeficiency virus type 1 integration and 2LTR formation in resting CD4+ T cellsGabriela Plesa, Jihong Dai, Cliff Baytop, et al.
Plos Pathogens|September 17, 2010
Steric shielding of surface epitopes and impaired immune recognition induced by the ebola virus glycoproteinJoseph R Francica, Angel Varela-Rohena, Andrew Medvec, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|January 28, 2010
HIV sequence variation associated with env antisense adoptive T-cell therapy in the hNSG mouse modelRithun Mukherjee, Gabriela Plesa, Scott Sherrill-Mix, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|February 25, 2017
Possible Compartmental Cytokine Release Syndrome in a Patient With Recurrent Ovarian Cancer After Treatment With Mesothelin-targeted CAR-T CellsJanos L Tanyi, Caitlin Stashwick, Gabriela Plesa, et al.
Human Vaccines & Immunotherapeutics|February 9, 2019
CRISPR/Cas9-based genome editing in the era of CAR T cell immunotherapyJanuary Salas-Mckee, Weimin Kong, Whitney L Gladney, et al.
Cancer Immunology, Immunotherapy : CII|June 20, 2014
Engineered T cells for cancer therapyCarl H June, Marcela V Maus, Gabriela Plesa, et al.
Science Translational Medicine|October 29, 2010
The inducible costimulator (ICOS) is critical for the development of human T(H)17 cellsChrystal M Paulos, Carmine Carpenito, Gabriela Plesa, et al.
Pageof 6

Showing results (1-10 of 53) with videos related to

Sort By:
Pageof 6
Immunotherapy|August 4, 2017
Overcoming barriers of car T-cell therapy in patients with mesothelin-expressing cancersMark H O'Hara, Caitlin Stashwick, Gabriela Plesa, et al.
Journal of Immunology (Baltimore, Md. : 1950)|April 9, 2008
Derivation and fluidity of acutely induced dysfunctional CD8+ T cellsGabriela Plesa, Adam E Snook, Scott A Waldman, et al.
Journal of Virology|June 16, 2006
Immunogenicity of cytopathic and noncytopathic viral vectorsGabriela Plesa, Philip M McKenna, Matthias J Schnell, et al.
Journal of Virology|October 12, 2007
Addition of deoxynucleosides enhances human immunodeficiency virus type 1 integration and 2LTR formation in resting CD4+ T cellsGabriela Plesa, Jihong Dai, Cliff Baytop, et al.
Plos Pathogens|September 17, 2010
Steric shielding of surface epitopes and impaired immune recognition induced by the ebola virus glycoproteinJoseph R Francica, Angel Varela-Rohena, Andrew Medvec, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|January 28, 2010
HIV sequence variation associated with env antisense adoptive T-cell therapy in the hNSG mouse modelRithun Mukherjee, Gabriela Plesa, Scott Sherrill-Mix, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|February 25, 2017
Possible Compartmental Cytokine Release Syndrome in a Patient With Recurrent Ovarian Cancer After Treatment With Mesothelin-targeted CAR-T CellsJanos L Tanyi, Caitlin Stashwick, Gabriela Plesa, et al.
Human Vaccines & Immunotherapeutics|February 9, 2019
CRISPR/Cas9-based genome editing in the era of CAR T cell immunotherapyJanuary Salas-Mckee, Weimin Kong, Whitney L Gladney, et al.
Cancer Immunology, Immunotherapy : CII|June 20, 2014
Engineered T cells for cancer therapyCarl H June, Marcela V Maus, Gabriela Plesa, et al.
Science Translational Medicine|October 29, 2010
The inducible costimulator (ICOS) is critical for the development of human T(H)17 cellsChrystal M Paulos, Carmine Carpenito, Gabriela Plesa, et al.
Pageof 6